PTC Therapeutics Inc PTCT:NASDAQ

Last Price$51.45NASDAQ Closing Price as of 4:00PM ET 8/19/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.65(1.25%)
Bid (Size)$47.12 (31)
Ask (Size)$55.19 (3)
Day Low / High$51.08 - 52.14
Volume314.5 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/19/2022

 

PTC Therapeutics Inc ( NASDAQ )

Price: $51.45
Change: -0.65 (1.25%)
Volume: 314.5 K
4:00PM ET 8/19/2022
 
 

ChemoCentryx Inc ( NASDAQ )

Price: $51.00
Change: 0.00 (0.00%)
Volume: 2.5 M
4:00PM ET 8/19/2022
 
 

Ultragenyx Pharmaceutical Inc ( NASDAQ )

Price: $49.03
Change: +0.36 (0.74%)
Volume: 430.4 K
4:00PM ET 8/19/2022
 
 

Amicus Therapeutics Inc ( NASDAQ )

Price: $11.85
Change: -0.21 (1.74%)
Volume: 1.7 M
4:00PM ET 8/19/2022
 
 

Insmed Inc ( NASDAQ )

Price: $25.13
Change: -0.57 (2.22%)
Volume: 590.5 K
4:00PM ET 8/19/2022
 

Read more news Recent News

Insider Sell: Ptc Therapeutics
9:08AM ET 8/12/2022 MT Newswires

Stephanie Okey, Director, on August 09, 2022, sold 2,296 shares in Ptc Therapeutics (PTCT) for $118,522. Following the Form 4 filing with the SEC, Okey has...

--Raymond James Adjusts PTC Therapeutics' Price Target to $60 From $55, Keeps Outperform Rating
10:28AM ET 8/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Credit Suisse Lifts PTC Therapeutics' Price Target to $55 from $52, Keeps Neutral Rating
10:37AM ET 8/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--RBC Raises Price Target on PTC Therapeutics to $49 From $46, Maintains Sector Perform Rating
8:17AM ET 8/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionPTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ. View company web site for more details
Address100 Corporate Court
South Plainfield, New Jersey 07080-2449
Phone+1.908.222.7000
Number of Employees517
Recent SEC Filing08/15/20228-K
Chief Executive Officer & DirectorStuart Walter Peltz
Chief Operating OfficerMatthew B. Klein
Chief Financial OfficerEmily Hill
Chief Technical Operations OfficerNeil Gregory Almstead

Company Highlights

Price Open$51.57
Previous Close$52.10
52 Week Range$25.01 - 54.46
Market Capitalization$3.7 B
Shares Outstanding71.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement10/27/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$7.99
Beta vs. S&P 500N/A
Revenue$264.7 M
Net Profit Margin-89.89%
Return on Equity1,335.54%

Analyst Ratings as of 03/01/2022

Buy
4
Overweight
1
Hold
5
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset